{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:43:48Z","timestamp":1790613828181,"version":"4.1.0"},"reference-count":151,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ymthe.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T02:10:29Z","timestamp":1649124629000},"page":"1810-1821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Monoclonal antibodies for malaria prevention"],"prefix":"10.1016","volume":"30","author":[{"given":"Maya","family":"Aleshnick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Florez-Cuadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5577-7787","authenticated-orcid":false,"given":"Brandon K.","family":"Wilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.04.001_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development - progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann. Med. Surg. (Lond)."},{"key":"10.1016\/j.ymthe.2022.04.001_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cmi.2018.04.024","article-title":"Monoclonal antibodies as anti-infective products: a promising future?","volume":"25","author":"Pelfrene","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ymthe.2022.04.001_bib3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/17460441.2019.1646723","article-title":"How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases?","volume":"14","author":"Laustsen","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.04.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10020-020-00162-6","article-title":"Antibody development for preventing the human respiratory syncytial virus pathology","volume":"26","author":"Soto","year":"2020","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2471\/BLT.16.178061","article-title":"Therapeutic antibodies for infectious diseases","volume":"95","author":"Sparrow","year":"2017","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ymthe.2022.04.001_bib6","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-019-02442-6","article-title":"Two Ebola drugs show promise amid ongoing outbreak","author":"Maxmen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1038\/s41598-021-84622-x","article-title":"In\u00a0vitro and in\u00a0vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP)","volume":"11","author":"Livingstone","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"e143958","DOI":"10.1172\/jci.insight.143958","article-title":"Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention","volume":"6","author":"Kisalu","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.04.001_bib13","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib14","doi-asserted-by":"crossref","first-page":"e003171","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"J.\u00a0Immunother. Cancer."},{"key":"10.1016\/j.ymthe.2022.04.001_bib15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4161\/mabs.24815","article-title":"Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies","volume":"5","author":"Passot","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2022.04.001_bib16","first-page":"109","article-title":"Pricing of monoclonal antibody therapies: higher if used for cancer?","volume":"24","author":"Hernandez","year":"2018","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ymthe.2022.04.001_bib17","series-title":"Government Agreement to Purchase Additional Doses of REGEN-COV\u2122 (Casirivimab and Imdevimab) Antibody Cocktail","author":"Regeneron Announces New","year":"2022"},{"key":"10.1016\/j.ymthe.2022.04.001_bib18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41590-021-01068-z","article-title":"Low-dose in\u00a0vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations","volume":"22","author":"Dussupt","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib19","doi-asserted-by":"crossref","first-page":"712122","DOI":"10.3389\/fimmu.2021.712122","article-title":"Broadly neutralizing antibodies for HIV-1 prevention","volume":"12","author":"Walsh","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib20","doi-asserted-by":"crossref","first-page":"e1002435","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.04.001_bib22","doi-asserted-by":"crossref","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against plasmodium falciparum malaria by PfSPZ vaccine","volume":"2","author":"Epstein","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.04.001_bib23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S\/AS01B with chimpanzee adenovirus 63 and modified vaccinia ankara vectored vaccines expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.04.001_bib24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","article-title":"Safety, immunogenicity, and protective efficacy against controlled human malaria infection of plasmodium falciparum sporozoite vaccine in Tanzanian adults","volume":"99","author":"Jongo","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ymthe.2022.04.001_bib25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1473-3099(19)30300-7","article-title":"Long-term incidence of severe malaria following RTS,S\/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial","volume":"19","author":"Tinto","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.04.001_bib26","doi-asserted-by":"crossref","first-page":"e0208328","DOI":"10.1371\/journal.pone.0208328","article-title":"First field efficacy trial of the Chad63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17\u00a0months old infants and children","volume":"13","author":"Tiono","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.04.001_bib27","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","author":"Oneko","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib28","doi-asserted-by":"crossref","first-page":"eaag2490","DOI":"10.1126\/scitranslmed.aag2490","article-title":"Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers","volume":"9","author":"McCall","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib29","doi-asserted-by":"crossref","first-page":"e1009576","DOI":"10.1371\/journal.pgen.1009576","article-title":"Whole-genome analysis of Malawian Plasmodium falciparum isolates identifies possible targets of allele-specific immunity to clinical malaria","volume":"17","author":"Shah","year":"2021","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymthe.2022.04.001_bib30","first-page":"taab117","article-title":"Antimalarial chemoprophylaxis and treatment in the USA: limited access and extreme price variability","author":"Frosch","year":"2021","journal-title":"J.\u00a0Trav. Med"},{"key":"10.1016\/j.ymthe.2022.04.001_bib31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4269\/ajtmh.15-0245","article-title":"Safety, tolerability, and compliance with long-term antimalarial chemoprophylaxis in American Soldiers in Afghanistan","volume":"93","author":"Saunders","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ymthe.2022.04.001_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4269\/ajtmh.2012.11-0511","article-title":"Compliance with antimalaria chemoprophylaxis in a combat zone","volume":"86","author":"Brisson","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ymthe.2022.04.001_bib33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4269\/ajtmh.2010.09-0774","article-title":"An outbreak of Plasmodium falciparum malaria in U.S. Marines deployed to Liberia","volume":"83","author":"Whitman","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ymthe.2022.04.001_bib34","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1016\/j.vaccine.2015.09.099","article-title":"Vaccine approaches to malaria control and elimination: insights from mathematical models","volume":"33","author":"White","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.04.001_bib35","doi-asserted-by":"crossref","first-page":"e00145","DOI":"10.1016\/j.parepi.2020.e00145","article-title":"Future use-cases of vaccines in malaria control and elimination","volume":"10","author":"Penny","year":"2020","journal-title":"Parasite Epidemiol. Control"},{"key":"10.1016\/j.ymthe.2022.04.001_bib36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12936-018-2549-1","article-title":"Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria","volume":"17","author":"Macintyre","year":"2018","journal-title":"Malar. J."},{"key":"10.1016\/j.ymthe.2022.04.001_bib37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.pt.2020.05.011","article-title":"When is a plasmodium-infected mosquito an infectious mosquito?","volume":"36","author":"Graumans","year":"2020","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.pt.2008.05.005","article-title":"Plasmodium development in the mosquito: biology bottlenecks and opportunities for mathematical modeling","volume":"24","author":"Drexler","year":"2008","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib39","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrmicro3111","article-title":"Looking under the skin: the first steps in malarial infection and immunity","volume":"11","author":"M\u00e9nard","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nm1350","article-title":"Quantitative imaging of Plasmodium transmission from mosquito to mammal","volume":"12","author":"Amino","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib41","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1462-5822.2006.00861.x","article-title":"Plasmodium sporozoites trickle out of the injection site","volume":"9","author":"Yamauchi","year":"2007","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.mib.2009.06.006","article-title":"Plasmodium sporozoite-host interactions from the dermis to the hepatocyte","volume":"12","author":"Ejigiri","year":"2009","journal-title":"Curr. Opin. Microbiol."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2022.04.001_bib43","doi-asserted-by":"crossref","first-page":"O6","DOI":"10.1186\/1475-2875-13-S1-O6","article-title":"The ins and outs of sporozoite biology in the dermis","volume":"13","author":"Hopp","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.ymthe.2022.04.001_bib44","doi-asserted-by":"crossref","first-page":"47613","DOI":"10.1074\/jbc.M208453200","article-title":"Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity","volume":"277","author":"Tewari","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.04.001_bib45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/385336a0","article-title":"Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes","volume":"385","author":"M\u00e9nard","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.04.001_bib46","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1074\/jbc.M106862200","article-title":"Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein","volume":"277","author":"Rathore","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.04.001_bib47","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2010.05.033","article-title":"The RTS,S malaria vaccine","volume":"28","author":"Casares","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.04.001_bib48","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm.4513","article-title":"A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein","volume":"24","author":"Tan","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib50","doi-asserted-by":"crossref","first-page":"eaau8529","DOI":"10.1126\/sciadv.aau8529","article-title":"Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts","volume":"4","author":"Oyen","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2022.04.001_bib51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1172\/JCI70349","article-title":"Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection","volume":"124","author":"Foquet","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.04.001_bib52","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1128\/IAI.01249-13","article-title":"Model for in\u00a0vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum","volume":"82","author":"Sack","year":"2014","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver","volume":"53","author":"Wang","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2022.04.001_bib54","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.chom.2021.03.011","article-title":"Partial protection against P. vivax infection diminishes hypnozoite burden and blood-stage relapses","volume":"29","author":"Sch\u00e4fer","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2022.04.001_bib55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pt.2016.12.011","article-title":"Theoretical implications of a pre-erythrocytic plasmodium vivax vaccine for preventing relapses","volume":"33","author":"White","year":"2017","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib56","doi-asserted-by":"crossref","first-page":"26951","DOI":"10.1074\/jbc.M109.013706","article-title":"Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate","volume":"284","author":"Plassmeyer","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.04.001_bib57","doi-asserted-by":"crossref","first-page":"e1010042","DOI":"10.1371\/journal.ppat.1010042","article-title":"The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in\u00a0vivo","volume":"17","author":"Flores-Garcia","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2022.04.001_bib58","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa2034031","article-title":"A monoclonal antibody for malaria prevention","volume":"385","author":"Gaudinski","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14760584.2017.1295853","article-title":"Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection","volume":"16","author":"Sack","year":"2017","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2022.04.001_bib60","doi-asserted-by":"crossref","first-page":"e153524","DOI":"10.1172\/jci.insight.153524","article-title":"Human antibodies against non-circumsporozoite proteins block Plasmodium falciparum parasite development in hepatocytes","volume":"7","author":"Fabra-Garc\u00eda","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.04.001_bib61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0092-8674(00)80511-5","article-title":"TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites","volume":"90","author":"Sultan","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.04.001_bib62","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/j.1460-2075.1993.tb05950.x","article-title":"Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes","volume":"12","author":"M\u00fcller","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2022.04.001_bib63","doi-asserted-by":"crossref","first-page":"e20621","DOI":"10.7554\/eLife.20621","article-title":"Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption","volume":"5","author":"Jimah","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2022.04.001_bib64","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1016\/j.vaccine.2014.06.033","article-title":"Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria na\u00efve adults","volume":"32","author":"Kester","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.04.001_bib65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-018-0084-2","article-title":"Safety and efficacy of novel malaria vaccine regimens of RTS,S\/AS01B alone, or with concomitant Chad63-MVA-vectored vaccines expressing ME-TRAP","volume":"3","author":"Rampling","year":"2018","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2022.04.001_bib66","doi-asserted-by":"crossref","first-page":"e00114-18","DOI":"10.1128\/IAI.00114-18","article-title":"Tailoring a plasmodium vivax vaccine to enhance efficacy through a combination of a CSP virus-like particle and TRAP viral vectors","volume":"86","author":"Atcheson","year":"2018","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib67","doi-asserted-by":"crossref","first-page":"e0216260","DOI":"10.1371\/journal.pone.0216260","article-title":"Design and assessment of TRAP-CSP fusion antigens as effective malaria vaccines","volume":"15","author":"Lu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.04.001_bib68","article-title":"Anti-TRAP\/SSP2 monoclonal antibodies can inhibit sporozoite infection and 1 enhance protection of anti-CSP monoclonal antibodies 2 3","author":"Wilder","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.ymthe.2022.04.001_bib69","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1365-2958.2005.05024.x","article-title":"CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts","volume":"59","author":"Kariu","year":"2006","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib70","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2011.06.053","article-title":"Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS","volume":"29","author":"Bergmann-Leitner","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.04.001_bib71","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.1073\/pnas.1633254100","article-title":"Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data","volume":"100","author":"Doolan","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.ymthe.2022.04.001_bib72","doi-asserted-by":"crossref","first-page":"e12294","DOI":"10.1371\/journal.pone.0012294","article-title":"Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei","volume":"5","author":"Bergmann-Leitner","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.04.001_bib73","doi-asserted-by":"crossref","first-page":"e00498-16","DOI":"10.1128\/IAI.00498-16","article-title":"The Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites as a candidate for preerythrocytic and transmission-blocking vaccines","volume":"85","author":"Espinosa","year":"2017","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib74","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1586\/14760584.2016.1141680","article-title":"Progress and prospects for blood-stage malaria vaccines","volume":"15","author":"Miura","year":"2016","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2022.04.001_bib75","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chom.2015.09.007","article-title":"Processing of plasmodium falciparum merozoite surface protein MSP1 activates a spectrin-binding function enabling parasite egress from RBCs","volume":"18","author":"Das","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2022.04.001_bib76","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.180.1.389","article-title":"Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein","volume":"180","author":"Blackman","year":"1994","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib77","doi-asserted-by":"crossref","first-page":"25655","DOI":"10.1074\/jbc.M114.586495","article-title":"The merozoite surface protein 1 complex is a platform for binding to human erythrocytes by plasmodium falciparum","volume":"289","author":"Lin","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.04.001_bib78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0166-6851(87)90189-7","article-title":"Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex","volume":"23","author":"McBride","year":"1987","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib79","doi-asserted-by":"crossref","first-page":"7703","DOI":"10.1074\/jbc.M115.698282","article-title":"Multiple plasmodium falciparum merozoite surface protein 1 complexes mediate merozoite binding to human erythrocytes","volume":"291","author":"Lin","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.04.001_bib80","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/IAI.74.2.1313-1322.2006","article-title":"Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum","volume":"74","author":"Woehlbier","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib81","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijpara.2008.10.006","article-title":"Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum","volume":"39","author":"Baum","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib82","doi-asserted-by":"crossref","first-page":"e96381","DOI":"10.1172\/jci.insight.96381","article-title":"Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions","volume":"2","author":"Payne","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.04.001_bib83","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41586-018-0779-6","article-title":"Structure of Plasmodium falciparum Rh5-CyRPA-Ripr invasion complex","volume":"565","author":"Wong","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.04.001_bib84","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chom.2016.06.004","article-title":"Essential role of the PfRh5\/PfRipr\/CyRPA complex during plasmodium falciparum invasion of erythrocytes","volume":"20","author":"Volz","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2022.04.001_bib85","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","article-title":"A PfRH5-based vaccine is efficacious against heterologous strain blood-stage plasmodium falciparum infection in Aotus monkeys","volume":"17","author":"Douglas","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2022.04.001_bib86","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","article-title":"Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination","volume":"2","author":"Minassian","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.ymthe.2022.04.001_bib87","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/1475-2875-13-326","article-title":"A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein","volume":"13","author":"Ord","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.ymthe.2022.04.001_bib88","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41467-019-09894-4","article-title":"A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates","volume":"10","author":"Douglas","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib89","doi-asserted-by":"crossref","first-page":"e13030","DOI":"10.1111\/cmi.13030","article-title":"Neutralising antibodies block the function of Rh5\/Ripr\/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes","volume":"21","author":"Healer","year":"2019","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib90","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/1475-2875-13-271","article-title":"Pregnancy-associated malaria and malaria in infants: an old problem with present consequences","volume":"13","author":"Moya-Alvarez","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.ymthe.2022.04.001_bib91","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1073\/pnas.1000951107","article-title":"Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA","volume":"107","author":"Srivastava","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.ymthe.2022.04.001_bib92","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.20041579","article-title":"Evidence for the involvement of VAR2CSA in pregnancy-associated malaria","volume":"200","author":"Salanti","year":"2004","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2022.04.001_bib93","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2958.2003.03570.x","article-title":"Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria","volume":"49","author":"Salanti","year":"2003","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib94","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.vaccine.2018.12.025","article-title":"Malaria vaccine trials in pregnant women: an imperative without precedent","volume":"37","author":"Healy","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.04.001_bib95","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.molbiopara.2007.06.007","article-title":"Structural polymorphism and diversifying selection on the pregnancy malaria vaccine candidate VAR2CSA","volume":"155","author":"Bockhorst","year":"2007","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib96","doi-asserted-by":"crossref","first-page":"E1129","DOI":"10.1503\/cmaj.202391","article-title":"The use and impact of monoclonal antibody biologics during pregnancy","volume":"193","author":"Pham-Huy","year":"2021","journal-title":"CMAJ"},{"key":"10.1016\/j.ymthe.2022.04.001_bib97","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1471-4922(01)01948-1","article-title":"An expanding ebl family of Plasmodium falciparum","volume":"17","author":"Adams","year":"2001","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib98","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1126\/science.1145213","article-title":"Erythrocyte receptors for (Plasmodium knowlesi) malaria: duffy blood group determinants","volume":"189","author":"Miller","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.04.001_bib99","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-3083.2007.02059.x","article-title":"Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission","volume":"67","author":"Ceravolo","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib100","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/s41564-019-0462-1","article-title":"Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody","volume":"4","author":"Rawlinson","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib101","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1128\/iai.62.12.5581-5586.1994","article-title":"Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein","volume":"62","author":"Tsuboi","year":"1994","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/CVI.05466-11","article-title":"Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein","volume":"19","author":"Ntumngia","year":"2012","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib103","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1128\/IAI.05924-11","article-title":"Conserved and variant epitopes of Plasmodium vivax duffy binding protein as targets of inhibitory monoclonal antibodies","volume":"80","author":"Ntumngia","year":"2012","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib104","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.4049\/jimmunol.1801631","article-title":"Identification and characterization of functional human monoclonal antibodies to plasmodium vivax duffy-binding protein","volume":"202","author":"Carias","year":"2019","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib105","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41564-019-0461-2","article-title":"Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP","volume":"4","author":"Urusova","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib106","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41586-018-0249-1","article-title":"Cryo-EM structure of an essential Plasmodium vivax invasion complex","volume":"559","author":"Gruszczyk","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.04.001_bib107","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1126\/science.aan1078","article-title":"Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax","volume":"359","author":"Gruszczyk","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.04.001_bib108","doi-asserted-by":"crossref","first-page":"e152465","DOI":"10.1172\/jci.insight.152465","article-title":"Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly","volume":"6","author":"Minassian","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.04.001_bib109","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/infdis\/jiaa287","article-title":"Antimalarial activity of artefenomel against asexual parasites and transmissible gametocytes during experimental blood-stage plasmodium vivax infection","volume":"225","author":"Collins","year":"2022","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.04.001_bib110","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI98012","article-title":"A controlled human malaria infection model enabling evaluation of transmission-blocking interventions","volume":"128","author":"Collins","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.04.001_bib111","doi-asserted-by":"crossref","first-page":"e0005139","DOI":"10.1371\/journal.pntd.0005139","article-title":"Safety and reproducibility of a clinical trial system using induced blood stage plasmodium vivax infection and its potential as a model to evaluate malaria transmission","volume":"10","author":"Griffin","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymthe.2022.04.001_bib112","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jit394","article-title":"Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers","volume":"208","author":"McCarthy","year":"2013","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.04.001_bib113","article-title":"Analysis of pre-erythrocytic immunity during plasmodium vivax infection reveals a diversity of responses that is partially due to blood stage cross-reactivity","author":"Ventocilla","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.ymthe.2022.04.001_bib114","doi-asserted-by":"crossref","first-page":"111375","DOI":"10.1016\/j.molbiopara.2021.111375","article-title":"The private life of malaria parasites: strategies for sexual reproduction","volume":"244","author":"Schneider","year":"2021","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib115","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1590\/0074-0276130597","article-title":"The Plasmodium bottleneck: malaria parasite losses in the mosquito vector","volume":"109","author":"Smith","year":"2014","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ymthe.2022.04.001_bib116","first-page":"976827","article-title":"The coming-out of malaria gametocytes","volume":"2010","author":"Kuehn","year":"2010","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib117","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/14760584.2021.1878028","article-title":"Transmission-blocking vaccines: harnessing herd immunity for malaria elimination","volume":"20","author":"Duffy","year":"2021","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2022.04.001_bib118","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14760584.2019.1674145","article-title":"Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development","volume":"18","author":"Miura","year":"2019","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2022.04.001_bib119","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4269\/ajtmh.2001.64.9","article-title":"Limited polymorphism in Plasmodium falciparum sexual-stage antigens","volume":"64","author":"Niederwieser","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ymthe.2022.04.001_bib120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12936-016-1263-0","article-title":"Global genetic diversity of the Plasmodium vivax transmission-blocking vaccine candidate Pvs48\/45","volume":"15","author":"Vallejo","year":"2016","journal-title":"Malar. J."},{"key":"10.1016\/j.ymthe.2022.04.001_bib121","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14760584.2021.1873135","article-title":"Structural vaccinology of malaria transmission-blocking vaccines","volume":"20","author":"Patel","year":"2021","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2022.04.001_bib122","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41541-021-00366-9","article-title":"Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes","volume":"6","author":"de Jong","year":"2021","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2022.04.001_bib123","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12828","article-title":"Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites","volume":"293","author":"de Jong","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2022.04.001_bib124","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3389\/fimmu.2019.01256","article-title":"Pfs230 and pfs48\/45 fusion proteins elicit strong transmission-blocking antibody responses against Plasmodium falciparum","volume":"10","author":"Singh","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib125","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41467-021-21775-3","article-title":"Predicting the public health impact of a malaria transmission-blocking vaccine","volume":"12","author":"Challenger","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib126","doi-asserted-by":"crossref","first-page":"110562","DOI":"10.1016\/j.jtbi.2020.110562","article-title":"Mathematical assessment of the impact of human-antibodies on sporogony during the within-mosquito dynamics of Plasmodium falciparum parasites","volume":"515","author":"Teboh-Ewungkem","year":"2021","journal-title":"J.\u00a0Theor. Biol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib127","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12936-021-03723-0","article-title":"Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone","volume":"20","author":"McCoy","year":"2021","journal-title":"Malar. J."},{"key":"10.1016\/j.ymthe.2022.04.001_bib128","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.vaccine.2014.07.030","article-title":"Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward","volume":"32","author":"Nunes","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.04.001_bib129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12936-018-2328-z","article-title":"Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study","volume":"17","author":"White","year":"2018","journal-title":"Malar. J."},{"key":"10.1016\/j.ymthe.2022.04.001_bib130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14760584.2017.1276833","article-title":"Towards clinical development of a Pfs48\/45-based transmission blocking malaria vaccine","volume":"16","author":"Theisen","year":"2017","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2022.04.001_bib131","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-3024.2003.00643.x","article-title":"Pfs230: from malaria transmission-blocking vaccine candidate toward function","volume":"25","author":"Williamson","year":"2003","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib132","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s42003-020-01123-9","article-title":"Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48\/45 proteins","volume":"3","author":"Singh","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib133","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-021-00383-8","article-title":"Preclinical development of a Pfs230-Pfs48\/45 chimeric malaria transmission-blocking vaccine","volume":"6","author":"Singh","year":"2021","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2022.04.001_bib134","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13071-016-1932-4","article-title":"Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate","volume":"10","author":"Zheng","year":"2017","journal-title":"Parasites Vectors."},{"key":"10.1016\/j.ymthe.2022.04.001_bib135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13071-021-04743-0","article-title":"Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria","volume":"14","author":"Yang","year":"2021","journal-title":"Parasites Vectors."},{"key":"10.1016\/j.ymthe.2022.04.001_bib136","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/IAI.70.3.1581-1590.2002","article-title":"Monoclonal antibody against the Plasmodium falciparum chitinase, PfCHT1, recognizes a malaria transmission-blocking epitope in Plasmodium gallinaceum ookinetes unrelated to the chitinase PgCHT1","volume":"70","author":"Langer","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib137","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1086\/432552","article-title":"An anti-Chitinase malaria transmission-blocking single-chain antibody as an effector molecule for creating a Plasmodium falciparum-refractory mosquito","volume":"192","author":"Li","year":"2005","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.04.001_bib138","doi-asserted-by":"crossref","first-page":"13461","DOI":"10.1073\/pnas.0702239104","article-title":"Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen","volume":"104","author":"Dinglasan","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.ymthe.2022.04.001_bib139","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nsmb.3048","article-title":"The Anopheles-midgut APN1 structure reveals a new malaria transmission-blocking vaccine epitope","volume":"22","author":"Atkinson","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib140","doi-asserted-by":"crossref","first-page":"729086","DOI":"10.3389\/fimmu.2021.729086","article-title":"Immunopotentiation by lymph-node targeting of a malaria transmission-blocking nanovaccine","volume":"12","author":"Howard","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib141","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-3024.2006.00807.x","article-title":"The immunomodulatory factors of arthropod saliva and the potential for these factors to serve as vaccine targets to prevent pathogen transmission","volume":"28","author":"Titus","year":"2006","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib142","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.chom.2018.03.008","article-title":"Immunization with AgTRIO, a protein in Anopheles saliva, contributes to protection against plasmodium infection in mice","volume":"23","author":"Dragovic","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2022.04.001_bib143","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/infdis\/jiaa759","article-title":"The effects of a mosquito salivary protein on sporozoite traversal of host cells","volume":"224","author":"Chuang","year":"2021","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.04.001_bib144","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1038\/s41467-018-05374-3","article-title":"A mosquito salivary gland protein partially inhibits Plasmodium sporozoite cell traversal and transmission","volume":"9","author":"Schleicher","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.04.001_bib145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/infdis\/jiy179","article-title":"Mosquito saliva: the hope for a universal arbovirus vaccine?","volume":"218","author":"Manning","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.04.001_bib146","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/S0140-6736(20)31048-5","article-title":"Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial","volume":"395","author":"Manning","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.04.001_bib147","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1038\/s41598-020-67877-8","article-title":"Bliss' and Loewe's additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations","volume":"10","author":"Azasi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.04.001_bib148","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2019.05.025","article-title":"Human antibodies that slow erythrocyte invasion potentiate malaria-neutralizing antibodies","volume":"178","author":"Alanine","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.04.001_bib149","doi-asserted-by":"crossref","first-page":"101381","DOI":"10.1016\/j.isci.2020.101381","article-title":"A humanized mouse model for plasmodium vivax to test interventions that block liver stage to blood stage transition and blood stage infection","volume":"23","author":"Sch\u00e4fer","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2022.04.001_bib150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2018.00524","article-title":"Plasmodium falciparum liver stage infection and transition to stable blood stage infection in liver-humanized and blood-humanized FRGN KO mice enables testing of blood stage inhibitory antibodies (reticulocyte-binding protein homolog 5) in\u00a0vivo","volume":"9","author":"Foquet","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.001_bib151","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/14760584.2019.1580577","article-title":"Human challenge models: tools to accelerate the development of malaria vaccines","volume":"18","author":"Cooper","year":"2019","journal-title":"Expert Rev. Vaccin."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622002295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622002295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:03:35Z","timestamp":1761501815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622002295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":151,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1525001622002295"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.04.001","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal antibodies for malaria prevention","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022","name":"copyright","label":"Copyright"}]}}